{
    "chemotherapy": {
        "title": "Common Chemotherapy Drugs",
        "description": "Core cytotoxic agents used in leukemia and solid tumor regimens.",
        "drugs": [
            {
                "name": "6-Mercaptopurine",
                "category": "Antimetabolite",
                "route": "Oral",
                "keyPoints": [
                    "Give on an empty stomach; avoid milk products.",
                    "Monitor CBC and liver enzymes regularly.",
                    "Adjust dose for hepatic impairment."
                ]
            },
            {
                "name": "Bleomycin",
                "category": "Antitumor Antibiotic",
                "route": "IV, IM, or subcutaneous",
                "keyPoints": [
                    "Monitor for pulmonary toxicity; perform baseline PFTs.",
                    "Observe for fever or chills after administration.",
                    "Avoid giving with high oxygen concentrations."
                ]
            },
            {
                "name": "Busulfan",
                "category": "Alkylating Agent",
                "route": "Oral or IV infusion",
                "keyPoints": [
                    "Monitor for bone marrow suppression.",
                    "Seizure prophylaxis may be required with high doses.",
                    "Check for pulmonary fibrosis with long-term use."
                ]
            },
            {
                "name": "Cisplatin",
                "category": "Platinum Compound",
                "route": "IV infusion",
                "keyPoints": [
                    "Pre- and post-hydration essential to prevent nephrotoxicity.",
                    "Monitor renal function and electrolytes (Mg, K).",
                    "May cause ototoxicity—assess hearing regularly."
                ]
            },
            {
                "name": "Cyclophosphamide",
                "category": "Alkylating Agent",
                "route": "IV infusion",
                "keyPoints": [
                    "Hydrate patient before and after administration.",
                    "Monitor urine output; risk of hemorrhagic cystitis.",
                    "Use mesna for uroprotection if ordered."
                ]
            },
            {
                "name": "Cytarabine (Ara-C)",
                "category": "Antimetabolite",
                "route": "IV infusion or subcutaneous",
                "keyPoints": [
                    "Monitor for cerebellar toxicity—perform neuro checks.",
                    "May cause conjunctivitis—use prophylactic steroid eye drops.",
                    "High-dose regimens require leucovorin rescue."
                ]
            },
            {
                "name": "Daunorubicin",
                "category": "Anthracycline Antibiotic",
                "route": "IV push (central line preferred)",
                "keyPoints": [
                    "Cardiotoxic—check baseline ejection fraction.",
                    "Use vesicant precautions; avoid extravasation.",
                    "Red-orange urine discoloration is expected."
                ]
            },
            {
                "name": "Doxorubicin",
                "category": "Anthracycline Antibiotic",
                "route": "IV push (central line preferred)",
                "keyPoints": [
                    "Cardiotoxic—obtain baseline ECG and ejection fraction.",
                    "Avoid extravasation; use vesicant precautions.",
                    "Causes red discoloration of urine for 24–48 hrs."
                ]
            },
            {
                "name": "Etoposide",
                "category": "Topoisomerase II Inhibitor",
                "route": "IV infusion or oral",
                "keyPoints": [
                    "Administer slowly to avoid hypotension.",
                    "Monitor CBC for bone marrow suppression.",
                    "Use infusion pump; avoid rapid bolus."
                ]
            },
            {
                "name": "Ifosfamide",
                "category": "Alkylating Agent",
                "route": "IV infusion",
                "keyPoints": [
                    "Always co-administer mesna for uroprotection.",
                    "Ensure aggressive hydration to prevent cystitis.",
                    "Monitor mental status—risk of CNS toxicity."
                ]
            },
            {
                "name": "Methotrexate",
                "category": "Antimetabolite",
                "route": "IV, oral, or intrathecal",
                "keyPoints": [
                    "Requires leucovorin (Calcium folinate) rescue for high doses.",
                    "Monitor renal function and maintain hydration.",
                    "Avoid NSAIDs and cotrimoxazole during therapy."
                ]
            },
            {
                "name": "Vincristine",
                "category": "Vinca Alkaloid",
                "route": "IV push (never intrathecal!)",
                "keyPoints": [
                    "Fatal if given intrathecally.",
                    "Monitor for peripheral neuropathy and constipation.",
                    "Use warm compresses if extravasation suspected."
                ]
            }
        ]
    },

    "targetedTherapy": {
        "title": "Common Targeted and Monoclonal Therapies",
        "description": "Targeted biologic and molecular agents used in cancer treatment.",
        "drugs": [
            {
                "name": "Atezolizumab",
                "category": "PD-L1 Inhibitor (Immunotherapy)",
                "route": "IV infusion",
                "keyPoints": [
                    "Observe for fatigue, rash, or colitis symptoms.",
                    "Assess for hepatitis or endocrinopathies.",
                    "Do not restart after severe immune toxicity without physician review."
                ]
            },
            {
                "name": "Bevacizumab",
                "category": "Monoclonal Antibody (VEGF Inhibitor)",
                "route": "IV infusion",
                "keyPoints": [
                    "Monitor blood pressure regularly.",
                    "Assess for proteinuria before each cycle.",
                    "Delay surgery until wound healing is complete."
                ]
            },
            {
                "name": "Bortezomib",
                "category": "Proteasome Inhibitor",
                "route": "IV or subcutaneous",
                "keyPoints": [
                    "Rotate injection sites to prevent local reactions.",
                    "Monitor for peripheral neuropathy.",
                    "Avoid intrathecal administration."
                ]
            },
            {
                "name": "Cetuximab",
                "category": "Monoclonal Antibody (EGFR Inhibitor)",
                "route": "IV infusion",
                "keyPoints": [
                    "Premedicate to prevent infusion reactions.",
                    "Monitor for acneiform rash—may indicate efficacy.",
                    "Use sunscreen; skin more sensitive to sunlight."
                ]
            },
            {
                "name": "Imatinib",
                "category": "Tyrosine Kinase Inhibitor",
                "route": "Oral",
                "keyPoints": [
                    "Take with food and a full glass of water.",
                    "Monitor for edema and liver function tests.",
                    "Assess CBC for cytopenias."
                ]
            },
            {
                "name": "Nivolumab",
                "category": "PD-1 Inhibitor (Immunotherapy)",
                "route": "IV infusion",
                "keyPoints": [
                    "Monitor for immune-related adverse events (colitis, hepatitis).",
                    "Assess thyroid and liver function regularly.",
                    "Interrupt therapy if severe autoimmune symptoms occur."
                ]
            },
            {
                "name": "Pembrolizumab",
                "category": "PD-1 Inhibitor (Immunotherapy)",
                "route": "IV infusion",
                "keyPoints": [
                    "Monitor for infusion reactions and immune toxicities.",
                    "Evaluate for cough or dyspnea—may indicate pneumonitis.",
                    "Delay doses if autoimmune toxicity suspected."
                ]
            },
            {
                "name": "Rituximab",
                "category": "Monoclonal Antibody (CD20)",
                "route": "IV infusion",
                "keyPoints": [
                    "Premedicate with antihistamine and acetaminophen.",
                    "Monitor for infusion reactions—especially first dose.",
                    "Avoid live vaccines during and after treatment."
                ]
            },
            {
                "name": "Sorafenib",
                "category": "Multikinase Inhibitor",
                "route": "Oral",
                "keyPoints": [
                    "Take on empty stomach (1 hr before or 2 hrs after meals).",
                    "Monitor for hand-foot skin reaction and hypertension.",
                    "Check liver function periodically."
                ]
            },
            {
                "name": "Trastuzumab",
                "category": "Monoclonal Antibody (HER2)",
                "route": "IV infusion",
                "keyPoints": [
                    "Cardiotoxic—monitor LVEF before and during therapy.",
                    "Observe for infusion-related reactions.",
                    "Do not give concurrently with anthracyclines."
                ]
            }
        ]
    },

    "adjuvant": {
        "title": "Adjuvant / Supportive Medications",
        "description": "Medications used to prevent or manage chemotherapy-related side effects and toxicities.",
        "drugs": [
            {
                "name": "Allopurinol",
                "category": "Uric Acid Reducer",
                "route": "Oral",
                "keyPoints": [
                    "Start before induction chemotherapy to prevent tumor lysis.",
                    "Encourage hydration and monitor uric acid levels."
                ]
            },
            {
                "name": "Aprepitant",
                "category": "NK1 Receptor Antagonist",
                "route": "Oral or IV (fosaprepitant)",
                "keyPoints": [
                    "Used with 5-HT3 antagonist and steroid for highly emetogenic chemo.",
                    "May reduce efficacy of hormonal contraceptives.",
                    "Monitor for fatigue and hiccups."
                ]
            },
            {
                "name": "Dexamethasone",
                "category": "Corticosteroid",
                "route": "IV or oral",
                "keyPoints": [
                    "Used for nausea prevention and as part of chemotherapy regimens.",
                    "Monitor blood sugar and signs of infection."
                ]
            },
            {
                "name": "Filgrastim (G-CSF)",
                "category": "Hematopoietic Growth Factor",
                "route": "Subcutaneous injection",
                "keyPoints": [
                    "Monitor CBC; stop when ANC > 1000 in two consecutive days."
                ]
            },
            {
                "name": "Furosemide",
                "category": "Loop Diuretic",
                "route": "IV or oral",
                "keyPoints": [
                    "Used to maintain urine output during high-dose cisplatin or hydration protocols.",
                    "Monitor potassium and hydration status.",
                    "Record input/output balance accurately."
                ]
            },
            {
                "name": "Leucovorin (Calcium Folinate)",
                "category": "Folinic Acid Rescue",
                "route": "IV or oral",
                "keyPoints": [
                    "Administer after high-dose methotrexate as rescue therapy.",
                    "Monitor methotrexate levels if available.",
                    "Do not confuse with folic acid (different indication)."
                ]
            },
            {
                "name": "Mesna",
                "category": "Uroprotectant",
                "route": "IV or oral",
                "keyPoints": [
                    "Always used with ifosfamide or high-dose cyclophosphamide.",
                    "Protects bladder from hemorrhagic cystitis.",
                    "Ensure hydration and monitor urine output."
                ]
            },
            {
                "name": "Ondansetron",
                "category": "Antiemetic",
                "route": "IV or oral",
                "keyPoints": [
                    "Administer 30 minutes before chemotherapy.",
                    "Monitor for headache and QT prolongation."
                ]
            },
            {
                "name": "Palonosetron",
                "category": "5-HT3 Antagonist (Antiemetic)",
                "route": "IV infusion",
                "keyPoints": [
                    "Long-acting antiemetic—effective for delayed nausea.",
                    "Usually given once per cycle before chemotherapy.",
                    "Monitor for constipation and headache."
                ]
            },
            {
                "name": "Pegfilgrastim",
                "category": "Long-acting G-CSF",
                "route": "Subcutaneous injection",
                "keyPoints": [
                    "Administer at least 24 hours after chemotherapy.",
                    "Do not give within 14 days before next cycle.",
                    "Monitor for bone pain and WBC response."
                ]
            }
        ]
    }
}
